Gladius Pharmaceuticals


Gladius Pharmaceuticals is a privately held biopharmaceutical company focused on the development of novel, once-daily antibiotics for empiric treatment of Gram-negative infections. GL-332, our lead product candidate, a once-daily cephalosporin with a novel uptake mechanism, has demonstrated broad spectrum efficacy against Gram-negative pathogens. We are developing GL-332 as a replacement for older generation cephalosporins for the treatment of bacterial infections, including those caused by MDR Pseudomonas aeruginosa. We have built an exceptional research and development team with deep expertise in the development of new antibiotics from discovery through approval.


Latest News

Published: April, 2019
Drug Resistance in Cystic Fibrosis Lung Infections Associated With Pseudomonas Bacteriophages
Learn More

Published: April, 2019
DNA-based PCR test accurately predicts antibiotic resistance
Learn More

Published: April, 2019
Skin Cultures May Aid in Prediction of Bloodstream Infection Pathogens
Learn More